Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound, opening up a new direct-to-consumer (DTC) channel that could shake up how the ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into ...